Antisense '98
8th to 9th October 1998
Invited Speakers: Antisense 98 Speakers * denotes invited speaker
Stanley T. Crooke
Edwin M. Southern
William Marshall
Claude Helene
Jiandong Chen
Brian Sproat
Paul Herrling*
Peter E. Nielsen
Karl-Heinz Altmann
Dan Mercola
Hermann Haller
Stan Stepkowski
Brett P. Monia
Ian Creese
Giampaolo Tortora
Nicholas M. Dean
Sudhir Agrawal
Arthur A. Levin
Ruth Duncan
Rosanne M. Crooke
Michael J Hope
Ian Gibson*
Ralph E Christoffersen
Bruce A. Chabner
Finbarr Cotter
Cathy M. Holt
Russell Martin
Daniel L. Kisner
Andy Dorr
Program:
Antisense 98 Preliminary Programme
* denotes invited speakers
7 October
8.00pm Cocktail Hour for all Delegates
8.30pm Speakers' Dinner
8 October
8.30am Keynote Address by Stanley T. Crooke, ISIS Pharmaceuticals
Progress in Understanding and Proving Mechanisms of Antisense
Molecular Mechanisms for Regulation of Gene Expression I
Session chair Stanley T. Crooke
9.15am Identification of RNA Targets, Edwin M. Southern, University of Oxford
9.45am Antisense as a Tool in Identifying Gene Function, William Marshall, Amgen
10.15 Coffee Break
10.45am Antigene Mechanisms,Claude Helene, Museum National d'Histoire Naturelle
11.15am Suppression of Oncoprotein to Activate
Tumor Suppressor Gene, Jiandong Chen, LSU Medical Centre
11.45am Ribozymes, Brian S. Sproat, Innovir GmbH
12.15 Conference Luncheon
12.45 Luncheon Keynote Speech by Paul Herrling*, Novartis
Novartis' Role in Developing Antisense Therapeutics
Molecular Mechanisms for Regulation of Gene Expression II
2.00pm PNA, Peter E. Nielsen, The Panum Institute
2.30pm Second Generation Antisense Oligonucleotides: Structure - Activity
Studies and the Design of Improved Signal Transduction Inhibitors, Karl-Heinz Altmann, Novartis
Pharmacological Applications I
Session Chair Dan Mercola, Sidney Kimmel Cancer Centre
3.00pm Vascular Biology: Diabetes, Inflammation, Hermann Haller, Max Delbruck Centre
3.30pm Immunological Applications: Transplantation, Stan Stepkowski, University of Texas
4.00pm Coffee Break
Pharmacological Applications II
4.15pm raf Kinases, Brett P. Monia, ISIS Pharmaceuticals
4.45pm Antisense Studies of CNS
Dopamine Receptor Function, Ian Creese, Rutgers University
5.15pm Giampaolo Tortora, Universita degli Studio di Napoli Federico II
5.45pm Protein Kinase C alpha, Nicholas M. Dean, ISIS Pharmaceuticals
6.15pm Wine and Cheese Reception
9 October
Pharmacokinetics & Delivery I
Session Chair Sudhir Agrawal, Hybridon
8.30am Modifying Oligos to Improve
Therapeutic Potential, Sudhir Agrawal
9.00am Tox and Pharmacokinetics in Animals, Arthur A. Levin, ISIS Pharmaceuticals
9.30am Challenges for Tissue Targeting and Intracellular Delivery, Ruth Duncan, University of London
10.00am Suborgan Distribution, Rosanne M. Crooke, ISIS Pharmaceuticals
10.30am Coffee Break
Pharmacokinetics & Delivery II
11.00am Lipid-Based Delivery, Michael J. Hope, INEX Pharmaceuticals
11.30am Uptake and Cell Surface
Receptors for Oligos and Ribozymes, Ian Gibson*, University of East Anglia
12.00pm Conference Luncheon
12.45pm Luncheon Keynote Speech by Ralph E. Christoffersen, Ribozyme Pharmaceuticals
High Throughput Screening with Ribozymes.
Clinical Trial Progress
Session Chair Bruce Chabner, Massachusetts General Hospital
1.30pm BCL-2, Finbarr Cotter, Institute of Child Health
2.00pm C-myc, Cathy M. Holt, The University of Sheffield
2.30pm Hybridon Drug Update, Russell Martin, Hybridon
3.00pm ISIS Clinical Trial Update, Daniel L. Kisner, ISIS Pharmaceuticals
3.30pm Clinical Trials Phase III, Andy Dorr, ISIS Pharmaceuticals
3.45pm Coffee Break
4.00pm Roundtable Discussion, with all Speakers and Moderators at Antisense 98 Coffee served throughout
5.00pm Conference closes
Registration :
Please contact One Events
The LightHouse
35 Sarsfeld Road
London SW12 8HQ, UK
Tel: +44(0)181 682 2772 Fax: +44(0)181 682 3344
Deadline for Abstracts: 1st August 1998
Email for Requests and Registration: one_events@msn.com